Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital....

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Egaña, Larraitz, Auzmendi-Iriarte, Jaione, Andermatten, Joaquin, Villanua, Jorge, Ruiz, Irune, Elua-Pinin, Alejandro, Aldaz, Paula, Querejeta, Arrate, Sarasqueta, Cristina, Zubia, Felix, Matheu, Ander, Samprón, Nicolas
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595088/
https://ncbi.nlm.nih.gov/pubmed/33116181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-75477-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires